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Abstract
Background: Increased expression of lipocalin 2 (LCN2) has been observed in several cancers. The aim of the
present study was to investigate LCN2 in endometrial cancer in relation to clinico-pathologic phenotype,
angiogenesis, markers of epithelial-mesenchymal transition (EMT), and patient survival.
Methods: Immunohistochemical staining was performed using a human LCN2 antibody on a population-based
series of endometrial cancer patients collected in Hordaland County (Norway) during 1981-1990 (n=256). Patients
were followed from the time of primary surgery until death or last follow-up in 2007. The median follow-up time for
survivors was 17 years. Gene expression data from a prospectively collected endometrial cancer series (n=76) and a
publicly available endometrial cancer series (n=111) was used for gene correlation studies.
Results: Expression of LCN2 protein, found in 49% of the cases, was associated with non-endometrioid histologic
type (p=0.001), nuclear grade 3 (p=0.001), >50% solid tumor growth (p=0.001), ER and PR negativity (p=0.028
and 0.006), and positive EZH2 expression (p<0.001). LCN2 expression was significantly associated with expression
of VEGF-A (p=0.021), although not with other angiogenesis markers examined (vascular proliferation index,
glomeruloid microvascular proliferation, VEGF-C, VEGF-D or bFGF2 expression). Further, LCN2 was not associated
with several EMT-related markers (E-cadherin, N-cadherin, P-cadherin, β-catenin), nor with vascular invasion (tumor
cells invading lymphatic or blood vessels). Notably, LCN2 was significantly associated with distant tumor
recurrences, as well as with the S100A family of metastasis related genes. Patients with tumors showing no LCN2
expression had the best outcome with 81% 5-year survival, compared to 73% for intermediate and 38% for the
small subgroup with strong LCN2 staining (p=0.007). In multivariate analysis, LCN2 expression was an independent
prognostic factor in addition to histologic grade and FIGO stage.
Conclusion: Increased LCN2 expression is associated with aggressive features and poor prognosis in endometrial
cancer.
Background
Lipocalin 2 (LCN2), or NGAL, is a secreted glycoprotein
belonging to the lipocalin protein family and was first
identified as a gene upregulated in mouse kidney cells
infected by SV-40 tumor virus [1]. Members of the lipo-
calin family bind small molecules and cell surface recep-
tors to form macromolecular complexes. They have been
previously classified as transport proteins, but it is now
clear that they are also involved in several processes
related to malignant tumors like cell proliferation, apop-
tosis and inflammation [2-5].
LCN2 protein is known to be secreted by epithelial
cells, macrophages, neutrophils and tumor cells [6,7],
and increased levels have been observed in plasma,
serum and urine in various conditions such as metastatic
breast and colorectal cancer, acute kidney injury, pan-
creatitis and preeclampsia [8-13]. In tumor tissue,
increased expression of LCN2 has been found in human
breast, colorectal, ovarian and pancreatic cancers [13-
16]. In a mouse model of breast cancer, LCN2 protein
expression increased during tumor progression and
returned to normal following regression [17].
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may be involved in epithelial-mesenchymal transition
(EMT). Colon carcinoma cells with high LCN2 expres-
sion were observed to have decreased cell-cell adhesion
due to a dissociation of β-catenin from E-cadherin [15].
Further, E-cadherin expression was down-regulated in
breast cancer cell lines overexpressing LCN2 [13], and
tumor cells showed an increased motility and invasive-
ness accompanied by upregulation of mesenchymal mar-
kers [13]. In other studies, ovarian cancer cell lines
undergoing EMT showed a decreased expression of both
LCN2 and E-cadherin [18]. With respect to angiogenesis,
studies of pancreatic cancer cells showed LCN2 to block
HUVEC endothelial cells tube formation and reduce
VEGF secretion [19]. LCN2 has been shown to inhibit
tumor angiogenesis by suppressing RAS-induced VEGF
expression in 4 T1 tumor cells [20], but to increase
angiogenesis in a different breast cancer model [21].
Thus, the interactions between LCN2 and EMT as well
as angiogenesis seem to be complex and may be a func-
tion of tissue context, tumor type and tumor model.
Recent studies of endometrial cancer have implicated
LCN2 in tumor progression. A microarray study showed
LCN2 to be the gene with largest fold change between
carcinomas and benign tissues such as hyperplasia and
normal endometrium. Validation by immunohistochem-
istry confirmed the increase of LCN2 expression from
atypical endometrial hyperplasia to carcinomas [22].
High expression of LCN2 protein together with its re-
ceptor SLC22A17 has been related to poorer prognosis
among endometrial cancer patients [23]. LCN2 mRNA
levels have been associated with different EMT-related
genes in a study of endometrial hyperplasia [24]. In
endometrial cancer cell lines, LCN2 seems to trigger
cytokine production, IL8 being the highest, and this re-
sponse has been suggested to improve cell survival func-
tions by preventing apoptosis and increase cell migration
[25].
The aim of our present study was to investigate LCN2
expression in endometrial tumors with respect to clin-
ico-pathologic phenotype, angiogenesis, EMT markers,
vascular invasion by tumor cells, inflammatory markers
and patient survival.
Methods
Patient series
All 316 patients diagnosed with endometrial carcinoma in
Hordaland County (Norway) during the period 1981-1990
were studied. This endometrial cancer series and the vari-
ables histologic type, histologic grade, nuclear grade, solid
growth, mitoses, estrogen receptor, progesterone receptor,
HER-2 expression and FIGO stage, have previously been
reported [26-29]. Several markers related to the EMT
process (E-cadherin, N-cadherin, P-cadherin, β-catenin)
and tumor vascular interactions (VEGF-A, VEGF-C,
VEGF-D, bFGF2, blood vascular invasion, lymphatic vas-
cular invasion, vascular proliferation index, glomeruloid
microvascular proliferation) have previously been reported
and were included for comparison in the present study
[27,28,30-32].
Follow-up information was collected from the medical
records and correspondence with primary physicians.
Patients were followed from the time of primary surgery
until death or last follow-up in 2007. The median follow-
up time for the survivors was 17 years (range 6 – 23 years);
256 cases with tissue available were included in the current
study.
This research was approved by the Norwegian Data In-
spectorate (961478–2), Norwegian Social Sciences Data
Services (15501), and local ethics committee (REKIII nr.
052.01). Written informed consent for participation in
the study was obtained from participants.
Immunohistochemistry
Staining of LCN2 was performed on 5 μm sections of
formalin-fixed and paraffin embedded tumors using
Figure 1 LCN2 protein expression: Immunohistochemical staining showing A) strong and B) no expression of LCN2 in endometrial
cancer (magnification x 400).
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10 minutes at 750 W followed by 350 W for 15 minutes
in 10 mM citrate buffer and stained with a rat monoclo-
nal LCN2 antibody (Clone #220310, MAB1757; R&D
Systems, Minneapolis, MN, USA). Pre-treatment with
goat serum diluted 1:4 was conducted before incuba-
tion with antibody diluted 1:25 for 1 hour at room
t e m p e r a t u r e( R T )f o l l o w e db y1 : 3 0 0d i l u t e dg o a ta n t i -
rat IgG-HRP (Santa Cruz, CA, USA) for 1 hour at
RT. The peroxidase was localized with diaminobenzi-
dine peroxidase (DAB, Dako, GLostrup, Denmark) as
substrate, and sections were counterstained with Dako
REAL hematoxylin (Dako).
TMA-slides were evaluated in a standard light
microscope (by MM and IMS). Regarding LCN2 expres-
sion, cytoplasmic staining intensity in tumor cells
(graded 0-3) and staining area (0, no tumor cells positive;
1, <10%; 2, 10%-50%; 3, >50%) were recorded. A stain-
ing index (SI) was calculated as a product of staining in-
tensity and positive area giving a staining index of 0-9
[33]. Cases were divided in two subgroups based on the
median value (positive cases with SI 1-9 versus negative
cases with SI 0). In the survival analysis, the subgroup
with strong expression (staining index 9) was shown in
addition.
Gene expression analysis
During 2001-2003, 76 cases of endometrial cancer were
prospectively collected at the Department of Gynecology
and Obstetrics, Haukeland University Hospital, University
of Bergen, Norway. Fresh tumor tissue was carefully dis-
sected from the surgical specimens and was immediately
frozen in liquid nitrogen and stored for later use at -80
oC.
Content of tumor cells (by estimated area) was at least
50%, and for the majority >80%.
Table 1 LCN2 protein expression by various
clinico-pathological variables and molecular markers
among 256 endometrial cancers
Variable LCN2 SI 0N
(%)
LCN2 SI 1-9N
(%)
P-
value
a
Histologic
type
Endometrioid 126 (55%) 103 (45%) 0.001
Non-
endometrioid
5 (19%) 22 (81%)
Histologic
grade
Grade
1 and 2
89 (56%) 71 (44%) 0.066
Grade 3 42 (44%) 54 (56%)
Nuclear
grade
Grade
1 and 2
101 (59%) 71 (41%) 0.001
Grade 3 30 (36%) 54 (64%)
Solid
growth
<50% 104 (56%) 82 (44%) 0.013
≥50% 27 (39%) 43 (61%)
Mitoses
b Low 103 (54%) 89 (46%) NS
High 28 (44%) 36 (56%)
FIGO
stage
c,d
I/II 109 (53%) 97 (47%) NS
III/IV 22 (45%) 27 (55%)
ER
e,f Negative 25 (40%) 38 (60%) 0.028
Positive 103 (56%) 82 (44%)
PR
g,h Negative 28 (38%) 46 (62%) 0.006
Positive 98 (57%) 74 (43%)
EZH2
i,j Weak 121 (56%) 94 (44%) <0.001
Strong 10 (24%) 31 (76%)
HER2
k,l Weak 115 (54%) 100 (46%) 0.084
Strong 11 (37%) 19 (63%)
VEGF-A
m,n Weak 114 (55%) 94 (45%) 0.021
Strong 17 (36%) 30 (64%)
aP-value from χ
2 test. Mitoses:
bmedian used as cut-off point. FIGO stage:
caccording to 1998 criteria,
dmissing data in one case. ER:
emissing data in 8
cases,
flower quartile used as cut-off point. PR:
gmissing data in 8 cases,
hlower
quartile used as cut-off point. EZH2:
imissing data in 10 cases,
jupper quartile
used as cut-off point HER2:
kmissing data in 11 cases,
lmedian used as cut-off
point and VEGF-A:
mmissing data in one case,
nupper quartile used as cut-off
point.
Table 2 Associations between LCN2 expression and
metastatic spread among 215 endometrial cancers
Variable Site of
tumor recurrence
LCN2 SI 0
N (%)
LCN2 SI
1-9N (%)
P-value
a
Recurrent disease
b No tumor recurrence 96 (55%) 78 (45%) 0.029
Vaginal cuff 11 (79%) 3 (21%)
Pelvic lymph nodes 2 (67%) 1 (33%)
Distant metastasis
(not liver)
9 (50%) 9 (50%)
Liver 0 (0%) 6 (100%)
aP-value from Pearson’s χ
2 test,
bMissing data for 41 patients.
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Log Rank test, p=0.007
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Figure 2 Survival analysis for LCN2: Univariate survival analysis
(Kaplan-Meier method, log-rank significance test) for LCN2 in
endometrial cancers.
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Hilden, Germany) and hybridized to Agilent Whole
Human Genome Microarrays 44 k (Cat.no. G4112F),
according to the manufacturer’s instructions (www.
agilent.com). Arrays were scanned using the Agilent
Microarray Scanner Bundle. Microarray signal inten-
sities were determined using BRB-ArrayTools (http://
linus.nci.nih.gov/BRB-ArrayTools/). Mean spot signal
data were used as intensity measure. The expression
data were normalized, using median over the entire array.
This data have been deposited in the ArrayExpress Archive
database, http://www.ebi.ac.uk/arrayexpress/ (ArrayExpress
accession: E-MTAB-1007).
In addition, a publicly available data set with information
on gene expression from endometrial cancer patients was
used for supplementary studies (NCBI GEO: GSE2109).
The GEO data sets were based on Affymetrix U133+2
arrays. For these data sets, individual probes were se-
quence-matched against Aceview (NCB135) to construct
transcript level probe sets [34].
Statistical methods
Statistical analyses were performed by the PASW statis-
tical software package version 17 (SPSS Inc., Chicago,
IL). Associations between different categorical variables
were assessed by Pearson’s chi-square test. An association
was considered significant if a p-value of <0.05 was
obtained. Univariate survival analyses were performed
using the Kaplan-Meier method (log-rank significance
test). LCN2, together with standard clinico-pathological
variables, was further analyzed by log-log plot to determine
how these variables could be incorporated in the Cox’ pro-
portional hazards regression model (likelihood ratio signifi-
cance test).
The PANTHER expression analysis tool was used for
gene ontology analysis of microarray data. Gene lists
were mapped to PANTHER for categorization of genes
to molecular function and biological processes, as well as
to biological pathways (http://pantherdb.org).
Results
In total, 125 (49%) of the endometrial cancers were posi-
tive for LCN2 cytoplasmic protein expression, while 131
(51%) of the cases were negative (median SI value was
0). Eight endometrial cancers (3%) had a very strong
cytoplasmic expression of LCN2 (SI=9) (Figure 1).
Clinico-pathologic features
LCN2 protein expression showed a significant associ-
ation with aggressive features such as non-endometrioid
histologic type, high nuclear grade, and predominant
solid tumor growth (>50%) (Table 1), but not with FIGO
stage or histological grade.
Metastatic pattern
Forty-one of 215 patients (16%) showed recurrence of
their primary endometrial cancer during the follow-up
period. Regarding the site of recurrent tumors, 34% were
located in the vagina, 7% in pelvic lymph nodes, 44%
represented distant metastases (liver not included), and
15% were metastases to the liver; 174 cases did not show
any spread of the disease. LCN2 expression in the pri-
mary tumor was significantly associated with pattern of
tumor recurrence (p=0.029; Table 2), and LCN2 staining
was especially related to the development of liver metas-
tases (p=0.008, Fisher exact test; Table 2).
Table 3 Multivariate survival analysis (Cox’ proportional
hazards regression model) of clinico-pathologic variables
and LCN2 expression in patients with endometrial cancer
(n=255)
Variables Categories HR
a 95% CI
b P-value
c
LCN2 Negative 1.0 0.027
Weak/moderate 1.1 0.6-1.9
Strong 3.9 1.4-10.8
Histologic type Endometrioid 1.0 NS
Non-endometrioid 1.7 0.9-3.2
Histologic grade Grade 1 and 2 1.0 <0.001
Grade 3 2.8 1.6-4.9
FIGO stage I/II 1.0 <0.001
III/IV 8.0 4.8-13.6
aAdjusted Hazard ratio,
b95% confidence interval,
cL ratio test.
Table 4 Correlation between gene expression for LCN2 and S100-genes in two different microarray data series
(Pearson’s correlation)
S100A2 S100A3 S100A6 S100A8 S100A9 S100A11 S100A14 S100A16
In house data series:
(n=76)
0.580 0.271 0.509 0.480 0.480 0.551 0.355 0.340
<0.001 0.018 <0.001 <0.001 <0.001 <0.001 0.002 0.003
External data series:
(n=111)
0.509 0.189 0.488 0.346 0.433 0.564 0.423 0.445
<0.001 0.039 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
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Absence of LCN2 staining was associated with the best
survival. Cases with medium staining index (SI 2-6)
showed an intermediate survival, whereas the subgroup of
patients showing strong LCN2 expression (staining index
9) was associated with the poorest outcome (Figure 2). In
multivariate survival analysis, standard clinico-pathologic
variables (histologic type, histologic grade, and FIGO
stage) were included together with LCN2 expression in
three groups. Strong LCN2 was an independent prognostic
marker for decreased survival, with Hazard ratio (HR) of
3.9, p=0.027 (Table 3). Histologic grade (HR 2.8, p<0.001),
and FIGO stage (HR 8.0, p<0.001) were independent prog-
nostic factors in addition, whereas histologic type was not
(HR 1.7, NS) (Table 3).
Associations with molecular markers
Strong LCN2 expression was significantly associated with
ER and PR negative tumors (Table 1), as well as with posi-
tive EZH2 expression (p<0.001). In contrast, LCN2 was
not associated with expression of several EMT-related
markers such as E-cadherin, N-cadherin, P-cadherin and
β-catenin. There was a significant association between
LCN2 staining and VEGF-A expression (p=0.021), whereas
LCN2 showed no significant associations with other angio-
genesis markers such as vascular proliferation index, glo-
meruloid microvascular proliferation, VEGF-C, VEGF-D
and bFGF2 expression, nor with vascular invasion of tumor
cells (in lymphatic or blood vessels).
Associations with gene expression data
PANTHER expression analysis was used to search for
over-represented biological processes and molecular
functions among tumors with high (median as cut-point)
LCN2 gene expression (fold change >1.5, false discovery
rate <10%, p-values <10
-4) (n=76). Gene expression
among cases with high LCN2 expression was signifi-
cantly related to integrin signaling as well as the bio-
logical processes of angiogenesis and cell adhesion.
Differential gene expression was further examined with
respect to known candidate genes for metastatic spread,
such as the S100A family in our prospective endometrial
cancer series (n=76) and in the public endometrial cancer
series (N=111) (NCBI GEO: GSE2109). Bivariate correl-
ation analyses of microarray expression data showed a
strong and consistent positive correlation between LCN2
gene expression and several S100A-genes, with significant
correlations in both series with S100A2, S100A3, S100A6,
S100A8, S100A9, S100A11, S100A14 and S100A16
(Table 4).
Discussion
In this study, we demonstrate that LCN2 expression is
associated poor outcome in endometrial carcinoma and
with aggressive features, including the non-endometrioid
histologic type, high grade and solid tumor growth. Similar
findings have been reported for other tumors including
breast cancer [13-15]. Approximately 50% of the tumors
in the present study were positive for LCN2 expression,
comparable to breast cancers with staining in 33% of the
cases [35].
LCN2 expression has been associated with ER negative,
PR negative and HER2 positive breast cancers [13,35-37].
Here, we found an association between LCN2 expression
and ER-PR negative endometrial cancers. A similar rela-
tionship was observed regarding HER2 status and LCN2,
but was of borderline significance only.
Interestingly, LCN2 expression was associated with
more distant metastatic spread in our series, espe-
cially to the liver, and gene expression data from two
independent series supported a relationship between
LCN2 and metastasis related genes such as the S100A
family [38-42]. In a breast cancer mouse model,
plasma samples from preclinical tumor-bearing mice
compared with control mice show an upregulated
protein expression of S100A8, S100A9, and LCN2
[17]. In addition, S100A8 and S100A9-activated colon
cancer cells showed an upregulation of LCN2 gene
expression compared to non-stimulated cells [38].
Our findings suggest that LCN2 expression might be
implicated in metastases regulation through an inter-
action with S100A proteins.
Previous studies indicate that LCN2 might be involved
in epithelial-mesenchymal transition (EMT) and meta-
static spread [13,18,19], consistent with our finding that
LCN2 expression is associated with distant metastatic
dissemination. Although there were no significant asso-
ciations with several specific EMT-related protein mar-
kers such as cadherins or β-catenin staining, gene
expression analysis by PANTHER still indicated a rela-
tionship between LCN2 and cell adhesion as well as
angiogenesis.
Finally, the data presented here demonstrate that
LCN2 expression predicts poor prognosis since cases
with strong staining showed a decreased survival com-
pared to those with no staining as demonstrated by
multivariate analysis.
Conclusions
Taken together, our data support associations between
LCN2 expression and aggressive tumor features, distant
metastatic spread and reduced survival in endometrial can-
cer. Interestingly, gene expression data indicated a relation-
ship with S100A genes. The mechanism is presently not
clear and should be further studied.
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